Answers are grounded in this paper and cite their sources.
Clinical trials for gene therapy in coronary restenosis are premature and basic research should be prioritized to overcome current biological and delivery obstacles.
The application of gene therapy techniques to the clinical problem of coronary restenosis has generated tremendous attention and enthusiasm. Use of gene transfer technology to prevent a common intractable illness would represent a watershed event for human gene therapy. However, the time is not yet right to initiate gene therapy trials for restenosis. The biology of restenosis is incompletely understood, catheter-based gene delivery is poorly adapted to the coronary circulation, and current gene transfer vectors are ill-suited for safe and effective gene delivery to the coronary artery wall. Basic research designed to overcome these obstacles is currently more appropriate than the initiation of clinical trials.
No takes yet. Share an insight, caveat, or question.
DeYoung et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: